Latest "Fluorouracil Leukovorin bevacizumab Colorectal Cancer" News Stories

19:18 EST 2nd December 2016 | BioPortfolio

Here are the most relevant search results for "Fluorouracil Leukovorin bevacizumab Colorectal Cancer" found in our extensive news archives from over 250 global news sources.

More Information about Fluorouracil Leukovorin bevacizumab Colorectal Cancer on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Fluorouracil Leukovorin bevacizumab Colorectal Cancer for you to read. Along with our medical data and news we also list Fluorouracil Leukovorin bevacizumab Colorectal Cancer Clinical Trials, which are updated daily. BioPortfolio also has a large database of Fluorouracil Leukovorin bevacizumab Colorectal Cancer Companies for you to search.

Showing "Fluorouracil Leukovorin bevacizumab Colorectal Cancer" News Articles 1–25 of 17,000+

Extremely Relevant

Hetero launches biosimilar Bevacizumab to treat metastatic colorectal cancer

Hetero, one of India's leading generic pharmaceutical companies, announced the launch of biosimilar 'Bevacizumab' in India for the treatment of metastatic colorectal cancer (mCRC) under the brand name 'Cizumab'.

Addition of Eloxatin® Following Surgery Delays Cancer Progression in Certain Colorectal Cancers

The addition of the chemotherapy combination consisting of Eloxatin (oxalipatin) plus 5-fluorouracil (5 FU) following surgery reduces the risk of cancer progression among patients with deficient mismatch repair (dMMR) stage III colorectal cancer. These results were recently published in the Journal of the National Cancer Institute. Among patients with colorectal cancer that has spread to […]...

Adjuvant Bevacizumab for Colorectal Cancer?

Adding bevacizumab to capecitabine did not improve survival for patients with stage III or high-risk stage II disease.

Low LDH May Predict Second-Line Bevacizumab CRC Response

The addition of bevacizumab to second-line chemotherapy in metastatic colorectal cancer could be targeted to patients with low lactate dehydrogenase (LDH) levels, say Italian scientists. Medscape Medical News

Middle-Aged Man With Acute Thrombocytopenia Subsequent to Fluorouracil and Oxaliplatin Chemotherapy for Colorectal Cancer

A 44-year-old patient with a history of stage IIB colorectal cancer at the hepatic flexure, invading the duodenum and pancreas, was initially diagnosed in September 2005 and received modified Whipple surgery and 8 cycles of adjuvant chemotherapy with capecitabine and oxaliplatin every 3 weeks.

Therapy: No benefit for adjuvant capecitabine plus bevacizumab in colorectal cancer

Oncolytics begins Phase II trial of Reolysin in female patients with colorectal cancer

Canadian-based biotechnology company Oncolytics has initiated the Phase II trial of Reolysin (pelareorep) in combination with FOLFOX6, bevacizumab and pembrolizumab in female patients with KRAS-mutant colorectal cancer (CRC) metastatic to the liver.

CXCR4 polymorphism predicts progression-free survival in metastatic colorectal cancer patients treated with first-line bevacizumab-based chemotherapy

Oncolytics Biotech® Inc. launches Phase 2 Study for female patients with colorectal cancer metastatic to the liver

CALGARY, AB – Oncolytics Biotech Inc. reports that following its submission to the U.S. Food and Drug Administration (FDA) for review, the Investigational New Drug Application containing the protocol titled “Phase 2 study of REOLYSIN® (pelareorep) in combination with FOLFOX6, bevacizumab and pembrolizumab in female patients with KRAS-mutant colorectal cancer metastatic to the liver...

FOLFOX Equals or Betters Epirubicin, Cisplatin, and Fluorouracil in Esophagogastric Cancer

Adding epirubicin to fluorouracil/platinum-based chemotherapy resulted in greater toxicity and no clear improvement in response.

BRIEF-Amgen says new retrospective analyses confirm Vectibix treatment provided survival benefit over chemotherapy with or without Bevacizumab

* New retrospective analyses confirm Vectibix (panitumumab) treatment provided survival benefit over chemotherapy with or without bevacizumab in metastatic colorectal cancer patients with tumors of left-sided origin Source text for Eikon: Further ...

Pretargeted radioimmunotherapy may eliminate colorectal cancer

An emerging cancer therapy has colorectal tumors surrounded. Presenters at the 2016 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI) are unveiling a novel radioimmunotherapy that combines a cancer-seeking antibody with potent radionuclide agents, resulting in complete remission of colorectal cancer in mouse models.

Genetic cause of 15% of all colorectal cancer diagnoses identified.

Colorectal cancer is the development of cancer from the colon or rectum, due to the abnormal growth of cells that have the ability to invade or spread to other parts of the body. Signs and symptoms may include blood in the stool, a change in bowel movements, weight loss, and feeling tired all the time.  Up to 15% of colorectal

How mouth microbes may worsen colorectal cancer

Bacteria commonly found in the mouth have been recently shown to worsen colorectal cancer in animals, but it has not been clear how these microbes make their way to the gut in the first place. A study published August 10 in Cell Host & Microbe sheds light on this question, revealing that oral microbes called fusobacteria may use the bloodstream to reach colorectal tumors. The findings also show ex...

Health policy expert discusses guidelines for colorectal cancer screening

Colorectal cancer is the second leading cause of death from cancer in the United States, after lung cancer, yet many Americans are still loathe to be screened for the disease.

Less than 3% of IBD patients develop colorectal cancer after colectomy

The prevalence and incidence of colorectal cancer among patients with inflammatory bowel disease is less than 3% after colectomy and less than 1% after ileal pouch-anal anastomosis, according to the results of a systematic review and meta-analysis.The researchers also identified residual rectum and history of colorectal cancer as risk factors for post-colectomy cancer risk.

Researchers block common colon cancer tumor type in mice

A new scientific study has identified why colorectal cancer cells depend on a specific nutrient, and a way to starve them of it. Over one million men and women are living with colorectal cancer in the United States. The National Cancer Institute estimates 4.5% of all men and women will be diagnosed with the cancer during their lifetime, making it the third most common non-skin cancer.

Retinoic acid suppresses colorectal cancer development

Retinoic acid, a compound derived in the body from vitamin A, plays a critical role in suppressing colorectal cancer in mice and humans, according to new research. Mice with colorectal cancer have lower-than-normal levels of the metabolite in their gut,...

Fecal Fat Points to Early Presence of Colorectal Cancer

Colorectal cancer (CRC) remains a leading cause of cancer mortality worldwide, and therefore more accessible screening tests are urgently needed...

Blood Test for Colorectal Cancer Recurrence Proves Highly Sensitive

When diagnosed early, before cancer has spread, the relative five-year survival rate for colorectal cancer (CRC) is 90%, but only...

CDC: US has sufficient health care resources to achieve CRC screening goals

CDC researchers estimate that U.S. health care facilities have the capacity to meet the National Colorectal Cancer Roundtable’s goal of screening at least 80% of adults aged 50 to 75 years for colorectal cancer by 2018.“Colorectal cancer is the second leading cancer killer for men and women in the U.S., but it doesn’t have to be,” Djenaba Joseph, MD, MPH, medical director of the colorectal...

Hispanic men in California need more screening for colorectal cancer

Colorectal cancer incidence and mortality rates in California have decreased markedly for men and women in all major racial-ethnic groups since 1990, except for Hispanic men. Colorectal cancer rates for Hispanic men have remained relatively the same, a...

Metabolite that promotes cancer cell transformation and colorectal cancer spread identified

Osaka University researchers revealed that the metabolite D-2-hydroxyglurate (D-2HG) promotes epithelial–mesenchymal transition of colorectal cancer cells, leading them to develop features of lower adherence to neighboring cells, increased invasiveness, and greater likelihood of metastatic spread. The finding highlights the value of targeting D-2HG to establish new therapeutic approaches against...


Chemotherapy Plus Bevacizumab Promising in Advanced TNBC

A triplet regimen including paclitaxel, capecitabine, and bevacizumab showed efficacy and safety in women with advanced triple-negative breast cancer.

Innovative Colorectal Cancer Screening Methods for Remote Areas

Colorectal cancer is the second-leading cause of cancer-related death in the United States, despite the fact that more than half of these deaths are avoidable with regular screenings. In fact, with screening, patients can prevent colon cancer from ever forming or catch it early enough to have a five-year survival rate of more than 90 […] The post Innovative Colorectal Cancer Screening Method...

Quick Search

News Quicklinks